Aeterna Zentaris Stock News

– Research agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis

Mumbai (Maharashtra) [India], March 8 (ANI/NewsVoir): Zoya, the exquisite diamond boutique from the House of Tata, introduces Aeterna a contemporary collection of rare jewellery that traces inspiration from ancient symbols of sacred geometry. Often described as a blueprint of the universe these symbols have captivated artists and philosophers across cultures and through the ages.

Aeterna Zentaris <> said its licensor, The University of Sheffield received a notice of allowance from the U.S. Patent and Trademark Office ((USPTO)).The patent application No

– Notice of allowance received by Company’s licensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyr

– Notice of allowance received by Company’s l icensor, The University of Sheffield (UK) bolsters intellectual property of AEZS-150 in development for the potential treatment of chronic hypoparathyroidism –

Epizyme (EPZM) delivered earnings and revenue surprises of -19.51% and 50.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aeterna Zentaris Inc. (NASDAQ:AEZS) with the stream of -2.85% also noticed, India Team, Inc. (NYSE:TISI) encountered a rapid change of -8.38% in the last hour of Tuesdays trading session. Aeterna The post Top Stock Picks for the Day: Aeterna Zentaris Inc. (NASDAQ:AEZS), Team, Inc. (NYSE:TISI) appeared first on Stocks Equity .

Synchronoss Technologies, Inc. (NASDAQ:SNCR) with the stream of -2.88% also noticed, India Aeterna Zentaris Inc. (NASDAQ:AEZS) encountered a rapid change of 1.94% in the last hour of Mondays trading session. The post Remarkable Stock in Review: Synchronoss Technologies, Inc. (NASDAQ:SNCR), Aeterna Zentaris Inc. (NASDAQ:AEZS) appeared first on Stocks Equity .

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commer

CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerci

Aeterna Zentaris (AEZS) receives a notice from Nasdaq, which grants an additional 180 calendar days, through Jul

CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commer

Aeterna Zentaris (AEZS) provided pipeline update and business outlook.Aeterna CEO Klaus Paulini said that in 2021 the company in-licensed six new pre-clinical development programs,…

– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023

– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET